Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer

Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer

Human epidermal growth factor receptor 2 (HER2) is a highly expressed tumor marker in epithelial ovarian cancer, and its overexpression is considered to be a potential factor of poor prognosis. Therefore, monitoring the expression of HER2 receptor in tumor tissue provides favorable conditions for ac...

Full description

Bibliographic Details
Main Authors: Xianwen Hu, Dandan Li, Yujie Fu, Jiashen Zheng, Zelong Feng, Jiong Cai, Pan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
human epidermal growth factor receptor
ovarian cancer
radionuclide
HER2 affibody
molecular probes
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.917439/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.917439/full

Similar Items